Antiinflammatory activity of ricinus communis derived polymer

Abstract

Aim: The present study aimed to evaluate the antiinflammatory activity of the polymer derived from Ricinus communis and its mechanism of action. Methods: The antiinflammatory activity was investigated in chronic and acute animal models and the mechanism of action involved in the antiinflammatory activity was determined by the in vitro phospholipase A2 (PLA2 ) enzyme assay. Results: In mouse ear edema (10.0 mg/ear) and granulomatous tissue formation (500 mg/kg) models, the polymer inhibited the inflammatory response in 75.08 ± 1.80% and 61.70 ± 1.80% of the cases, respectively (p<0.001). Oral administration of the Ricinus communis polymer (500 mg/kg) inhibited 72.00 ± 1.20% of formalin-induced inflammation. Topical administration of the polymer on oral lesions of mice showed that the oral mucosa was recovered in 60.00 ± 1.40% (p<0.05) of the cases. In in vitro assay, the phospholipase A2 enzyme was inhibited by the Ricinus communis polymer (5.0 mg/mL) in a dose-dependent manner (84.60 ± 1.41%). Conclusion: the polymer derived from Ricinus communis showed a significant antiinflammatory activity, confirming that the pharmacological mechanism involved in this antiinflammatory action was related to the inhibition of the PLA2 enzyme.